The fibrillin microfibril scaffold: A niche for growth factors and mechanosensation?

Matrix Biology

Volumn 47, Issue , 2015, Pages 3-12

  Sengle, Gerhard ^a   Sakai, Lynn Y ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Bone morphogenetic protein; Fibrillin; LTBP; Marfan syndrome; Mechanosensation; TGF ; Weill Marchesani syndrome

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; FIBRILLIN; FIBRILLIN 1; GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; ACTIN BINDING PROTEIN; BONE MORPHOGENETIC PROTEIN;

CELL INTERACTION; FIBER; MARFAN SYNDROME; MECHANICAL STRESS; MECHANOTRANSDUCTION; MICROENVIRONMENT; MOLECULAR INTERACTION; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; REVIEW; WEILL MARCHESANI SYNDROME; ANIMAL; EXTRACELLULAR MATRIX; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BONE MORPHOGENETIC PROTEINS; EXTRACELLULAR MATRIX; HUMANS; MARFAN SYNDROME; MECHANOTRANSDUCTION, CELLULAR; MICROFIBRILS; MICROFILAMENT PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84943665692     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2015.05.002     Document Type: Review

References (79)

1. Low F.N. Microfibrils: fine filamentous components of the tissue space. Anat Rec 1962, 142:131-137.
2. Sakai L.Y., Keene D.R., Engvall E. Fibrillin, a new 350-kD glycoprotein, is a component of extracellular microfibrils. J Cell Biol 1986, 103:2499-2509.
3. Sakai L.Y., Keene D.R., Glanville R.W., Bächinger H.P. Purification and partial characterization of fibrillin, a cysteine-rich structural component of connective tissue microfibrils. J Biol Chem 1991, 266:14763-14770.
4. Keene D.R., Maddox B.K., Kuo H.J., Sakai L.Y., Glanville R.W. J Histochem Cytochem 1991, 39:441-449.
5. Gibson M.A., Hughes J.L., Fanning J.C., Cleary E.G. The major antigen of elastin-associated microfibrils is a 31-kDa glycoprotein. J Biol Chem 1986, 261:11429-11436.
6. Gibson M.A., Hatzinikolas G., Kumaratilake J.S., Sandberg L.B., Nicholl J.K., Sutherland G.R., et al. Further characterization of proteins associated with elastic fiber microfibrils including the molecular cloning of MAGP-2 (MP25). J Biol Chem 1996, 271:1096-1103.
7. Reinboth B., Hanssen E., Cleary E.G., Gibson M.A. Molecular interactions of biglycan and decorin with elastic fiber components: biglycan forms a ternary complex with tropoelastin and microfibril-associated glycoprotein 1. J Biol Chem 2002, 277:3950-3957.
8. Isogai Z., Aspberg A., Keene D.R., Ono R.N., Reinhardt D.P., Sakai L.Y. Versican interacts with fibrillin-1 and links extracellular microfibrils to other connective tissue networks. J Biol Chem 2002, 277:4565-4572.
9. Tiedemann K., Sasaki T., Gustafsson E., Göhring W., Bätge B., Notbohm H., et al. Microfibrils at basement membrane zones interact with perlecan via fibrillin-1. J Biol Chem 2005, 280:11404-11412.
10. Reinhardt D.P., Sasaki T., Dzamba B.J., Keene D.R., Chu M.L., Göhring W., et al. J Biol Chem 1996, 271:19489-19496.
11. El-Hallous E., Sasaki T., Hubmacher D., Getie M., Tiedemann K., Brinckmann J., et al. Fibrillin-1 interactions with fibulins depend on the first hybrid domain and provide an adaptor function to tropoelastin. J Biol Chem 2007, 282:8935-8946.
12. Jensen S.A., Reinhardt D.P., Gibson M.A., Weiss A.S. Protein interaction studies of MAGP-1 with tropoelastin and fibrillin-1. J Biol Chem 2001, 276:39661-39666.
13. Tsutsui K., Manabe R., Yamada T., Nakano I., Oguri Y., Keene D.R., et al. ADAMTSL-6 is a novel extracellular matrix protein that binds to fibrillin-1 and promotes fibrillin-1 fibril formation. J Biol Chem 2010, 285:4870-4882.
14. Robertson I., Jensen S., Handford P. TB domain proteins: evolutionary insights into the multifaceted roles of fibrillins and LTBPs. Biochem J 2011, 433:263-276.
15. Weinbaum J.S., Broekelmann T.J., Pierce R.A., Werneck C.C., Segade F., Craft C.S., et al. Deficiency in microfibril-associated glycoprotein-1 leads to complex phenotypes in multiple organ systems. J Biol Chem 2008, 283:25533-25543.
16. Dabovic B., Robertson I.B., Zilberberg L., Vassallo M., Davis E.C., Rifkin D.B. Function of latent TGFβ binding protein 4 and fibulin 5 in elastogenesis and lung development. J Cell Physiol 2015, 230:226-236.
17. Maslen C.L., Corson G.M., Maddox B.K., Glanville R.W., Sakai L.Y. Partial sequence of a candidate gene for the Marfan syndrome. Nature 1991, 352:334-337.
18. Corson G.M., Chalberg S.C., Dietz H.C., Charbonneau N.L., Sakai L.Y. Fibrillin binds calcium and is coded by cDNAs that reveal a multidomain structure and alternatively spliced exons at the 5' end. Genomics 1993, 17:476-484.
19. Kanzaki T., Olofsson A., Moren A., Wernstedt C., Hellman U., Miyazono K., et al. TGF-beta 1 binding protein: a component of the large latent complex of TGFbeta 1 with multiple repeat sequences. Cell 1990, 61:1051-1061.
20. Hollister D.W., Godfrey M., Sakai L.Y., Pyeritz R.E. Immunohistologic abnormalities of the microfibrillar-fiber system in the Marfan syndrome. N Engl J Med 1990, 323:152-159.
21. Dietz H.C., Cutting G.R., Pyeritz R.E., Maslen C.L., Sakai L.Y., Corson G.M., et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 1991, 352:337-339.
22. Putnam E.A., Zhang H., Ramirez F., Milewicz D.M. Fibrillin-2 (FBN2) mutations result in the Marfan-like disorder, congenital contractural arachnodactyly. Nat Genet 1995, 11:456-458.
23. Isogai Z., Ono R.N., Ushiro S., Keene D.R., Chen Y., Mazzieri R., et al. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem 2003, 278:2750-2757.
24. Unsold C., Hyytiainen M., Bruckner-Tuderman L., Keski-Oja J. Latent TGF-beta binding protein LTBP-1 contains three potential extracellular matrix interacting domains. J Cell Sci 2001, 114:187-197.
25. Gregory K.E., Ono R.N., Charbonneau N.L., Kuo C.L., Keene D.R., Bächinger H.P., et al. The prodomain of BMP-7 targets the BMP-7 complex to the extracellular matrix. J Biol Chem 2005, 280:27970-27980.
26. Sengle G., Charbonneau N.L., Ono R.N., Sasaki T., Alvarez J., Keene D.R., et al. Targeting of bone morphogenetic protein growth factor complexes to fibrillin. J Biol Chem 2008, 283:13874-13888.
27. Dallas S.L., Miyazono K., Skerry T.M., Mundy G.R., Bonewald L.F. Dual role for the latent transforming growth factor-beta binding protein in storage of latent TGF-beta in the extracellular matrix and as a structural matrix protein. J Cell Biol 1995, 131:539-549.
28. Ono R.N., Sengle G., Charbonneau N.L., Carlberg V., Bächinger H.P., Sasaki T., et al. Latent transforming growth factor beta-binding proteins and fibulins compete for fibrillin-1 and exhibit exquisite specificities in binding sites. J Biol Chem 2009, 284:16872-16881.
29. Hirani R., Hanssen E., Gibson M.A. LTBP-2 specifically interacts with the amino-terminal region of fibrillin-1 and competes with LTBP-1 for binding to this microfibrillar protein. Matrix Biol 2007, 26:213-223.
30. Zilberberg L., Todorovic V., Dabovic B., Horiguchi M., Courousse T., Sakai L.Y., et al. Specificity of latent TGF-β binding protein (LTBP) incorporation into matrix: role of fibrillins and fibronectin. J Cell Physiol 2012, 227:3828-3836.
31. Saharinen J., Keski-Oja J. Specific sequence motif of 8-Cys repeats of TGF-beta binding proteins, LTBPs, creates a hydrophobic interaction surface for binding of small latent TGF-beta. Mol Biol Cell 2000, 11:2691-2704.
32. Neptune E.R., Frischmeyer P.A., Arking D.E., Myers L., Bunton T.E., Gayraud B., et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003, 33:407-411.
33. Habashi J.P., Judge D.P., Holm T.M., Cohn R.D., Loeys B.L., Cooper T.K., et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006, 312:117-121.
34. Ng C.M., Cheng A., Meyers L.A., Martinez-Murillo F., Jie C., Bedja D., et al. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest 2004, 114:1586-1592.
35. Cohn R.D., van Erp C., Habashi J.P., Soleimani A.A., Klein E.C., Lisi M.T., et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 2007, 13:204-210.
36. Judge D.P., Biery N.J., Keene D.R., Geubtner J., Myers L., Huso D.L., et al. Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. J Clin Invest 2004, 114:172-181.
37. Charbonneau N.L., Carlson E.J., Tufa S., Sengle G., Manalo E.C., Carlberg V.M., et al. In vivo studies of mutant fibrillin-1 microfibrils. J Biol Chem 2010, 285:24943-24955.
38. Sengle G., Ono R.N., Sasaki T., Sakai L.Y. Prodomains of transforming growth factor beta (TGFbeta) superfamily members specify different functions: extracellular matrix interactions and growth factor bioavailability. J Biol Chem 2011, 286:5087-5099.
39. Shi M., Zhu J., Wang R., Chen X., Mi L., Walz T., et al. Latent TGF-β structure and activation. Nature 2011, 474:343-349.
40. Sengle G., Ono R.N., Lyons K.M., Bächinger H.P., Sakai L.Y. A new model for growth factor activation: type II receptors compete with the prodomain for BMP-7. J Mol Biol 2008, 381:1025-1039.
41. Nistala H., Lee-Arteaga S., Smaldone S., Siciliano G., Carta L., Ono R.N., et al. Fibrillin-1 and -2 differentially modulate endogenous TGF-β and BMP bioavailability during bone formation. J Cell Biol 2010, 190:1107-1121.
42. Reinhardt D.P., Keene D.R., Corson G.M., Pöschl E., Bächinger H.P., Gambee J.E., et al. Fibrillin-1: organization in microfibrils and structural properties. J Mol Biol 1996, 258:104-116.
43. Baldock C., Koster A.J., Ziese U., Rock M.J., Sherratt M.J., Kadler K.E., et al. The supramolecular organization of fibrillin-rich microfibrils. J Cell Biol 2001, 152:1045-1056.
44. Lin G., Tiedemann K., Vollbrandt T., Peters H., Batge B., Brinckmann J., et al. Homo- and heterotypic fibrillin-1 and -2 interactions constitute the basis for the assembly of microfibrils. J Biol Chem 2002, 277:50795-50804.
45. Marson A., Rock M.J., Cain S.A., Freeman L.J., Morgan A., Mellody K., et al. Homotypic fibrillin-1 interactions in microfibril assembly. J Biol Chem 2005, 280:5013-5021.
46. Hubmacher D., El-Hallous E.I., Nelea V., Kaartinen M.T., Lee E.R., Reinhardt D.P. Biogenesis of extracellular microfibrils: multimerization of the fibrillin-1 C terminus into bead-like structures enables self-assembly. Proc Natl Acad Sci U S A 2008, 105:6548-6553.
47. Reinhardt D.P., Ono R.N., Notbohm H., Müller P.K., Bächinger H.P., Sakai L.Y. Mutations in calcium-binding epidermal growth factor modules render fibrillin-1 susceptible to proteolysis. A potential disease-causing mechanism in Marfan syndrome. J Biol Chem 2000, 275:12339-12345.
48. Doyle J.J., Gerber E.E., Dietz H.C. Matrix-dependent perturbation of TGFβ signaling and disease. FEBS Lett 2012, 586:2003-2015.
49. Mizuguchi T., Collod-Beroud G., Akiyama T., Abifadel M., Harada N., Morisaki T., et al. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet 2004, 36:855-860.
50. Loeys B.L., Chen J., Neptune E.R., Judge D.P., Podowski M., Holm T., et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 2005, 37:275-281.
51. van de Laar I.M., Oldenburg R.A., Pals G., Roos-Hesselink J.W., de Graaf B.M., Verhagen J.M., et al. Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet 2011, 43:121-126.
52. Doyle A.J., Doyle J.J., Bessling S.L., Maragh S., Lindsay M.E., Schepers D., et al. Mutations in the TGF-β repressor SKI cause Shprintzen-Goldberg syndrome with aortic aneurysm. Nat Genet 2012, 44:1249-1254.
53. Carmignac V., Thevenon J., Ades L., Callewaert B., Julia S., Thauvin-Robinet C., et al. In-frame mutations in exon 1 of SKI cause dominant Shprintzen-Goldberg syndrome. Am J Hum Genet 2012, 91:950-957.
54. Boileau C., Guo D.C., Hanna N., Regalado E.S., Detaint D., Gong L., et al. Go Exome Sequencing Project, Jondeau G, Milewicz DM. TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome. Nat Genet 2012, 44:916-921.
55. Lindsay M.E., Schepers D., Bolar N.A., Doyle J.J., Gallo E., Fert-Bober J., et al. Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm. Nat Genet 2012, 44:922-927.
56. Li W., Li Q., Jiao Y., Qin L., Ali R., Zhou J., et al. Tgfbr2 disruption in postnatal smooth muscle impairs aortic wall homeostasis. J Clin Invest 2014, 124:755-767.
57. Lacro R.V., Dietz H.C., Sleeper L.A., Yetman A.T., Bradley T.J., Colan S.D., et al. Pediatric Heart Network Investigators. Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med 2014, 371:2061-2071.
58. Chen X., Lu H., Rateri D.L., Cassis L.A., Daugherty A. Conundrum of angiotensin II and TGF-β interactions in aortic aneurysms. Curr Opin Pharmacol 2013, 13:180-185.
59. Cook J.R., Clayton N.P., Carta L., Galatioto J., Chiu E., Smaldone S., et al. Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome. Arteriosler Thromb Vasc. Biol 2015, 35:911-917.
60. Lönnqvist L., Child A., Kainulainen K., Davidson R., Puhakka L., Peltonen L. A novel mutation of the fibrillin gene causing ectopia lentis. Genomics 1994, 19:573-576.
61. Milewicz D.M., Grossfield J., Cao S.N., Kielty C., Covitz W., Jewett T. A mutation in FBN1 disrupts profibrillin processing and results in isolated skeletal features of the Marfan syndrome. J Clin Invest 1995, 95:2373-2378.
62. Faivre L., Gorlin R.J., Wirtz M.K., Godfrey M., Dagoneau N., Samples J.R., et al. In frame fibrillin-1 gene deletion in autosomal dominant Weill-Marchesani syndrome. J Med Genet 2003, 40:34-36.
63. McKusick V.A. The Weill-Marchesani syndrome. Heritable disorders of connective tissue 1972, 282-291. CV Mosby Company, St. Louis, MO. 4th ed. V.A. McKusick (Ed.).
64. Le Goff C., Mahaut C., Wang L.W., Allali S., Abhyankar A., Jensen S., et al. Mutations in the TGFβ binding protein-like domain 5 of FBN1 are responsible for acromicric and geleophysic dysplasia. Am J Hum Genet 2011, 89:7-14.
65. Sengle G., Tsutsui K., Keene D.R., Tufa S.F., Carlson E.J., Charbonneau N.L., et al. Microenvironmental regulation by fibrillin-1. PLoS Genet 2012, 8:e1002425.
66. Loeys B.L., Gerber E.E., Riegert-Johnson D., Iqbal S., Whiteman P., McConnell V., et al. Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome. Sci Transl Med 2010, (2):23ra20.
67. Sporn M.B. The early history of TGF-β, and a brief glimpse of its future. Cytokine Growth Factor Rev 2006, 17:3-7.
68. Tamminen J.A., Parviainen V., Rönty M., Wohl A.P., Murray L., Joenväärä S., et al. Oncogenesis 2013, 2:e66.
69. Gerber E.E., Gallo E.M., Fontana S.C., Davis E.C., Wigley F.M., Huso D.L., et al. Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma. Nature 2013, 503:126-130.
70. Pfaff M., Reinhardt D.P., Sakai L.Y., Timpl R. Cell adhesion and integrin binding to recombinant fibrillin-1. FEBS Lett 1996, 384:247-250.
71. Sakamoto H., Broekelmann T., Cheresh D.A., Ramirez F., Rosenbloom J., Mecham R.P. Cell-type specific recognition of RGD- and non-RGD-containing cell binding domains in fibrillin-1. J Biol Chem 1996, 271:4916-4922.
72. Jovanovic J., Takagi J., Choulier L., Abrescia N.G., Stuart D.I., van der Merwe P.A., et al. alphaVbeta6 is a novel receptor for human fibrillin-1. Comparative studies of molecular determinants underlying integrin-rgd affinity and specificity. J Biol Chem 2007, 282:6743-6751.
73. Bax D.V., Bernard S.E., Lomas A., Morgan A., Humphries J., Shuttleworth C.A., et al. Cell adhesion to fibrillin-1 molecules and microfibrils is mediated by alpha 5 beta 1 and alpha v beta 3 integrins. J Biol Chem 2003, 278:34605-34616.
74. Cain S.A., McGovern A., Baldwin A.K., Baldock C., Kielty C.M. Fibrillin-1 mutations causing Weill-Marchesani syndrome and acromicric and geleophysic dysplasias disrupt heparan sulfate interactions. PLoS One 2012, 7:e48634.
75. Zou Y., Akazawa H., Qin Y., Sano M., Takano H., Minamino T., et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 2004, 6:499-506.
76. Cook J.R., Carta L., Benard L., Chemaly E.R., Chiu E., Rao S.K., et al. Abnormal muscle mechanosignaling triggers cardiomyopathy in mice with Marfan syndrome. J Clin Invest 2014, 124:1329-1339.
77. De Backer J.F., Devos D., Segers P., Matthys D., Francois K., Gillebert T.C., et al. Primary impairment of left ventricular function in Marfan syndrome. Int J Cardiol 2006, 112:353-358.
78. Humphrey J.D., Milewicz D.M., Tellides G., Schwartz M.A. Cell biology. Dysfunctional mechanosensing in aneurysms. Science 2014, 344:477-479.
79. Kuo C.L., Isogai Z., Keene D.R., Hazeki N., Ono R.N., Sengle G., et al. Effects of fibrillin-1 degradation on microfibril ultrastructure. J Biol Chem 2007, 282:4007-4020.